SI2477648T1 - Sinergijska terapija proti CD47 za krvne rake - Google Patents

Sinergijska terapija proti CD47 za krvne rake

Info

Publication number
SI2477648T1
SI2477648T1 SI201032114T SI201032114T SI2477648T1 SI 2477648 T1 SI2477648 T1 SI 2477648T1 SI 201032114 T SI201032114 T SI 201032114T SI 201032114 T SI201032114 T SI 201032114T SI 2477648 T1 SI2477648 T1 SI 2477648T1
Authority
SI
Slovenia
Prior art keywords
therapy
synergistic anti
hematologic cancers
hematologic
cancers
Prior art date
Application number
SI201032114T
Other languages
English (en)
Inventor
Irving L. Weissman
Ravindra Majeti
Arash Ash Alizadeh
Mark P. Chao
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43758999&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2477648(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of SI2477648T1 publication Critical patent/SI2477648T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
SI201032114T 2009-09-15 2010-09-15 Sinergijska terapija proti CD47 za krvne rake SI2477648T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27672609P 2009-09-15 2009-09-15
EP10817793.2A EP2477648B1 (en) 2009-09-15 2010-09-15 Synergistic anti-cd47 therapy for hematologic cancers
PCT/US2010/048992 WO2011034969A1 (en) 2009-09-15 2010-09-15 Synergistic anti-cd47 therapy for hematologic cancers

Publications (1)

Publication Number Publication Date
SI2477648T1 true SI2477648T1 (sl) 2022-09-30

Family

ID=43758999

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201032114T SI2477648T1 (sl) 2009-09-15 2010-09-15 Sinergijska terapija proti CD47 za krvne rake

Country Status (9)

Country Link
US (4) US8758750B2 (sl)
EP (2) EP4134095A1 (sl)
AU (1) AU2010295661B2 (sl)
CA (2) CA2771336C (sl)
ES (1) ES2927646T3 (sl)
PL (1) PL2477648T3 (sl)
PT (1) PT2477648T (sl)
SI (1) SI2477648T1 (sl)
WO (1) WO2011034969A1 (sl)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711370C (en) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
US11072655B2 (en) 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
CA3054220C (en) 2008-01-15 2022-10-11 The Board Of Trustees Of The Leland Stanford Junior University Methods for manilpulating phagocytosis mediated by cd47
EP2111869A1 (en) * 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
US9873918B2 (en) 2011-08-11 2018-01-23 Albert Einstein College Of Medicine, Inc. Treatment of acute myeloid leukemia and myelodysplastic syndromes
MX360772B (es) 2012-02-06 2018-11-15 Inhibrx Inc Anticuerpos cd47 y metodos de uso de los mismos.
WO2013173820A2 (en) * 2012-05-18 2013-11-21 Scott & White Healthcare Bispecific scfv immunofusion (bif)
US11059910B2 (en) * 2012-12-03 2021-07-13 Novimmune Sa Anti-CD47 antibodies and methods of use thereof
BR112015013431A2 (pt) 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
US9873747B2 (en) 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
AU2014244083B2 (en) * 2013-03-13 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
ES2728066T3 (es) 2013-03-15 2019-10-22 Univ Leland Stanford Junior Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47
WO2014186761A2 (en) * 2013-05-17 2014-11-20 The Board Of Trustes Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-cd47 agent
NL2011904C2 (en) * 2013-12-06 2015-06-09 Stichting Vu Vumc Leukemic stem cell markers.
JP6560682B2 (ja) * 2014-01-08 2019-08-14 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 小細胞肺癌に対する標的療法
AU2015229448B2 (en) 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
ES2962260T3 (es) * 2014-08-08 2024-03-18 Univ Leland Stanford Junior Proteínas de fusión SIRPa alfa-anticuerpo
PL3180363T3 (pl) 2014-08-15 2020-02-28 Merck Patent Gmbh Białka fuzyjne immunoglobulin sirp-alfa
HUE052725T2 (hu) * 2014-08-26 2021-05-28 Univ Leland Stanford Junior Õssejtek beültetése õssejteket célzó hatóanyag és immunszabályozó szignalizáció módosításának kombinációjával
WO2016057980A1 (en) * 2014-10-10 2016-04-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting cd47
KR102313073B1 (ko) * 2014-12-05 2021-10-18 리제너론 파마슈티칼스 인코포레이티드 인간화 분화 클러스터 47 유전자를 가진 비인간 동물
BR112017014258A2 (pt) 2014-12-30 2018-03-06 Celgene Corp anticorpos anti-cd47 e usos dos mesmos
KR20170136535A (ko) * 2015-03-18 2017-12-11 메모리얼 슬로안-케터링 캔서 센터 조혈성 및 림프성 악성종양에서 cd99를 표적화하는 조성물 및 방법
PL3341015T5 (pl) 2015-08-26 2024-04-08 The Board Of Trustees Of The Leland Stanford Junior University Zwiększona deplecja komórek docelowych z blokadą cd47 i immunologicznym agonistą kostymulatorowym
RU2748401C2 (ru) 2015-09-18 2021-05-25 Арч Онколоджи, Инк. Терапевтические антитела к CD47
AU2016326423A1 (en) 2015-09-21 2018-04-26 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
PT3380525T (pt) * 2015-11-25 2024-02-05 Immunogen Inc Formulações farmacêuticas e métodos que as utilizam
EP3708587A1 (en) 2015-11-27 2020-09-16 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
US10946042B2 (en) * 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells
KR20220163516A (ko) 2016-01-11 2022-12-09 포티 세븐, 인코포레이티드 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
CA3011429A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents
AU2017250029C1 (en) * 2016-04-15 2022-03-24 Pfizer Inc. Macrophage stimulation in CD47 blockade therapy
WO2017190148A1 (en) 2016-04-29 2017-11-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the prevention and treatment of surgical adhesions
AU2017271588B2 (en) 2016-05-27 2022-01-20 Agenus Inc. Anti-TIM-3 antibodies and methods of use thereof
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
US20200181713A1 (en) * 2016-08-03 2020-06-11 Cbmed Gmbh Center For Biomarker Research In Medicine Method for prognosing and diagnosing tumors
CN109862910A (zh) 2016-08-03 2019-06-07 小利兰·斯坦福大学托管委员会 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
WO2018057802A1 (en) 2016-09-21 2018-03-29 Aptevo Research And Development Llc Cd123 binding proteins and related compositions and methods
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
WO2018081448A1 (en) 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
EP3345924A1 (en) 2017-01-10 2018-07-11 Universität Duisburg-Essen Use of cd47 antibodies
CA3055957A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
KR20200019619A (ko) * 2017-06-21 2020-02-24 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 혈액성 악성종양에 대한 cd47 표적 요법을 위한 투약 파라미터
US11401329B2 (en) 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
CN117771364A (zh) 2017-10-18 2024-03-29 四十七公司 基于抗cd47剂的卵巢癌疗法
WO2019086574A1 (en) * 2017-11-01 2019-05-09 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 and cd33 antigen-binding molecules
US20220298254A1 (en) 2017-11-01 2022-09-22 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 antigen-binding molecules
CN111699005A (zh) 2018-02-12 2020-09-22 四十七公司 使用抗cd47抗体和抗cd20抗体的抗癌方案
CN110305212A (zh) 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
KR20210032454A (ko) * 2018-07-17 2021-03-24 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능성 세포로부터의 분화 세포
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
MX2021006134A (es) 2018-11-26 2021-06-23 Forty Seven Inc Anticuerpos humanizados contra c-kit.
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
CA3153636A1 (en) * 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
CN110755635B (zh) * 2019-11-14 2022-10-11 天津大学 Flu@α-cd47@RGD制剂的合成方法
US20210221886A1 (en) * 2019-12-05 2021-07-22 Sorrento Therapeutics, Inc. Compositions and Methods Comprising an Anti-CD47 Antibody in Combination with a Tumor Targeting Antibody
EP4262828A1 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
US20230071148A1 (en) * 2021-07-15 2023-03-09 Vcreate, Inc. Compositions and Methods for Making Novel T-Cell Receptors
WO2023165618A1 (en) * 2022-03-04 2023-09-07 Nanjing University Methods for treating cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
EP0771208B1 (en) 1994-08-12 2005-10-19 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
FR2741892B1 (fr) 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus
CA2226962A1 (en) * 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20040001828A1 (en) * 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
US20050180972A1 (en) * 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
US8101719B2 (en) 2003-11-11 2012-01-24 Chugai Seiyaku Kabushiki Kaisha Humanized anti-CD47 antibody
US7601355B2 (en) 2005-06-01 2009-10-13 Northwestern University Compositions and methods for altering immune function
US20090191202A1 (en) 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
EP2139922A1 (en) 2007-03-28 2010-01-06 Biogen Idec, Inc. Treatment of hodgkins lymphoma
CA3054220C (en) 2008-01-15 2022-10-11 The Board Of Trustees Of The Leland Stanford Junior University Methods for manilpulating phagocytosis mediated by cd47
CA2711370C (en) * 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
EP2111869A1 (en) * 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system

Also Published As

Publication number Publication date
CA2771336A1 (en) 2011-03-24
US20210214437A1 (en) 2021-07-15
US8758750B2 (en) 2014-06-24
US20140369924A1 (en) 2014-12-18
EP2477648A4 (en) 2013-05-08
PL2477648T3 (pl) 2022-11-07
US20120282174A1 (en) 2012-11-08
ES2927646T3 (es) 2022-11-08
AU2010295661A1 (en) 2012-03-22
EP2477648B1 (en) 2022-07-20
EP2477648A1 (en) 2012-07-25
EP4134095A1 (en) 2023-02-15
CA3057650A1 (en) 2011-03-24
AU2010295661B2 (en) 2015-04-30
US20190048075A1 (en) 2019-02-14
PT2477648T (pt) 2022-10-27
WO2011034969A1 (en) 2011-03-24
CA2771336C (en) 2019-11-26

Similar Documents

Publication Publication Date Title
EP2477648A4 (en) SYNERGISTIC ANTI-CD47 THERAPY FOR HEMATOLOGICAL CANCER
HUS1800001I1 (hu) Kombinációs terápia COPD-hez
HK1200363A1 (en) Compounds useful for treating cancer
HK1175476A1 (en) Cancer treatment
IL206654A0 (en) Combination therapy
PL2440287T3 (pl) Urządzenie do terapii fotodynamicznej
HK1174571A1 (en) Combination therapy for copd copd
EP2506875A4 (en) METHOD FOR THE TREATMENT OF TUMORS WITH K-RAS MUTATIONS
EP2621497A4 (en) ASSOCIATION TREATMENT FOR ROSE ACNE
PT2957292T (pt) Terapia de vitiligo
GB201013898D0 (en) Well treatment
GB0901465D0 (en) Compounds for use in therapy
ZA201201894B (en) Pharmaceutical combination for treating tumor
GB0916997D0 (en) Combination therapy
GB0803948D0 (en) Combination therapy
GB0707556D0 (en) Treatment for cancer
GB0809046D0 (en) Cancer treatment
GB0907973D0 (en) Combination therapy
GB0913603D0 (en) Cancer therapy
GB0921102D0 (en) Cancer Therapy
GB0914441D0 (en) Compound for therapy
GB0903080D0 (en) Compound for therapy
GB0901497D0 (en) Compound for therapy
GB0921244D0 (en) Therapy
GB0914820D0 (en) WATerian therapy